Focused On-demand Library for Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8IYT2

UPID:

CMTR2_HUMAN

Alternative names:

Cap methyltransferase 2; Cap2 2'O-ribose methyltransferase 2; FtsJ methyltransferase domain-containing protein 1; Protein adrift homolog

Alternative UPACC:

Q8IYT2; B2RCD5; D3DWS1; Q8NE77; Q8NFR5; Q9H8Z4; Q9NUS3; Q9NXF5

Background:

Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2, also known as Cap methyltransferase 2, plays a crucial role in mRNA processing. It is responsible for the S-adenosyl-L-methionine-dependent methylation of mRNA cap2 2'-O-ribose, enhancing the stability and efficiency of mRNA translation. This protein's ability to recognize and methylate the ribose of the second nucleotide of a capped mRNA, regardless of the N(7) methylation status of the guanosine cap, underscores its specificity and importance in RNA metabolism.

Therapeutic significance:

Understanding the role of Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2 could open doors to potential therapeutic strategies. Its pivotal function in mRNA processing and translation regulation suggests that modulating its activity could influence gene expression patterns, offering new avenues for treating diseases with underlying genetic and mRNA processing anomalies.